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Abstract 
 
Aims/hypothesis Beta cell development is sensitive to glucocorticoid levels. Although direct 
effects of glucocorticoids on pancreatic precursors have been shown to control beta cell mass 
expansion, indirect effects of these hormones on pancreatic development remain unexplored. 
This issue was addressed in mice lacking the glucocorticoid receptor (GR) in the whole 
organism. 
Methods The pancreatic phenotype of GRnull/null mice was studied at fetal ages (embryonic day 
[E]) E15.5 and E18 by immunohistochemistry and beta cell fraction measurements. To 
distinguish between direct and indirect effects, mutant E15.5 fetal pancreata were grafted 
under the kidney capsule of immunodeficient mice and analysed after 1 week.  
Results E18 GRnull/null fetuses showed smaller digestive tracts and tiny pancreata. Massive 
pancreatic disorganisation and apoptosis were observed despite the presence of all cell types. 
E15.5 GRnull/null mutants were indistinguishable from wild-type regarding pancreatic size, 
tissue structure and organisation, beta cell fraction and expression of exocrine transcription 
factor Ptf1a, neurogenin 3 and Pdx-1. Grafting E15.5 GRnull/null pancreata into a GR-expressing 
environment rescued the increased apoptosis and mature islets were observed, suggesting that 
GRnull/null pancreatic cell death can be attributed to indirect effects of glucocorticoids on this 
tissue. Heterozygous GR+/null mutants with reduced GR numbers showed no apoptosis but 
increased beta cell fraction at E18 and the adult age, strengthening the importance of an 
accurate GR dosage on beta cell mass expansion.  
Conclusions/interpretation Our results provide evidence for GR involvement in pancreatic 
tissue organisation and survival through indirect effects. GR does not appear necessary for 
early phases but its accurate dosage is critical to modulate beta cell mass expansion at later 
fetal stages, presumably through direct effects. 
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Abbreviations 
BrdU: 5-bromo-2’-deoxyuridine 
GR: glucocorticoid receptor 
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SCID: severe combined immunodeficiency 
TUNEL: terminal transferase-mediated X-dUTP nick end labelling 
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Introduction 
Glucocorticoids are involved in various important physiological processes including immune 
responses and inflammation, carbohydrate, protein and lipid metabolism and cardiovascular 
function, as well as behavioural and neurobiological effects (for review see [1]). They may 
participate in the coordination of these processes since their circulating levels vary with a 
circadian rhythm and in response to stress. Glucocorticoids are synthesised in the adrenal 
cortex and secreted into the blood. Circulating levels of glucocorticoids are tightly regulated 
both through the hypothalamus–pituitary–adrenal axis [2] and locally in the target tissues, by 
the expression of the 11β-hydroxysteroid dehydrogenase isoforms that control the balance 
between active and inactive steroids [3]. Glucocorticoids exert their effects by binding to the 
glucocorticoid receptor (GR), which is widely expressed [4-6], and in a few cell types by 
binding to the mineralocorticoid receptor [2]. Bound to its ligand, the GR is an active 
transcription factor that can both activate and inhibit the expression of target genes either after 
binding to DNA or through protein–protein interactions [6]. 
 During the past decade, the possibility that fetal events may influence the risk of 
disease in adulthood has generated considerable interest. Individuals who were thin at birth 
are at increased risk of cardiovascular disease (including hypertension) and glucose 
intolerance or type 2 diabetes in adulthood [7-10]. From these epidemiological findings the 
concept of early programming of adult diseases arose. The mechanisms by which fetal 
undernutrition and/or low birthweight increases the risk of developing these diseases are 
unclear. A dysfunction of stress response including increased circulating glucocorticoid levels 
is suspected in the aetiology of several metabolic disorders such as type 2 diabetes. In humans 
it is known that prenatal exposure to prednisone or maternal Cushing’s syndrome is associated 
with intra-uterine growth retardation (IUGR) [11, 12]. In rodents, fetal exposure to 
glucocorticoids induces IUGR at birth, and impaired glucose tolerance [13-15] and 
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hypertension [16, 17] at adult age. Numerous studies have investigated the deleterious effects 
of glucocorticoids on pancreatic beta cell function, showing altered glucose-stimulated insulin 
release, both in vitro in islets treated with dexamethasone [18-20] and in vivo in mice 
overexpressing GR in the beta cells [21, 22]. 
 Few results are yet available on the effects of these hormones on their target tissues 
during development. However, such effects in early life could ultimately lead to metabolic 
diseases in adulthood. The analysis of mice in which the GR has been genetically modified, 
GRhypo/hypo (also designated GR−/− [6, 23] and GRnull/null [6, 24, 25]), has provided evidence for a 
role of the GR in the development or function of several tissues, including fetal lung, adrenal 
and erythroblasts, and this modification is associated with neonatal death. We have previously 
shown that undernutrition during the last week of gestation in the rat increases both maternal 
and fetal glucocorticoid levels, which further causes decreased fetal pancreatic beta cell mass 
[26, 27]. In addition, in normally nourished rat fetuses increased beta cell mass was associated 
with low corticosterone levels, while decreased beta cell mass was observed under conditions 
of fetal overexposure to these hormones [28]. Beta cell development is thus sensitive to 
glucocorticoids. More precisely, the conditional inactivation of the GR in all pancreatic 
progenitors (GRPdx-Cre mice) led to a doubling of beta cell mass [29].  
 In addition to direct effects, there may also be indirect effects of glucocorticoids in the 
aetiology of the metabolic syndrome. In the present work we have explored whether 
impairing GR signalling in the whole organism similarly affects pancreatic development by 
studying the pancreatic phenotype of mouse fetuses carrying a deletion of exon 3 of the gene 
encoding GR, leading to a total absence of any GR protein carrying the DNA- or ligand-
binding domains (GRnull/null mice). To decipher the role of GR in pancreatic and islet 
development we also studied at fetal and adult ages the pancreatic phenotype of heterozygous 
GR+/null mutants. 
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Materials and methods 
 
Mouse breeding GRnull/+ mice [6, 30] were on a C57BL/6 and 129Sve/V mixed genetic 
background. Animals were, however, backcrossed to C57BL/6 for five or six generations. 
Seven-week-old male severe combined immunodeficiency (SCID) mice (Charles River, 
L’Arbresle, France) were bred in isolators supplied with sterile-filtered, temperature-
controlled air, as previously described [31]. The animals were housed with a 12-h light–dark 
cycle, and fed freely with a standard laboratory mouse chow (UAR A04; Villemoisson-sur-
Orge, France). 
  
Dissection and genotyping The experiments on mice were carried out according to the 
‘Principles of laboratory animal care’, National Institutes of Health (NIH) and French law, 
(authorisation No. 7612 granted to B. Breant by the French Agricultural Ministry). Pregnant 
female mice were killed by decapitation and the fetuses were quickly removed from the 
uterine horns and placed on ice-cold PBS. All fetuses including the mutants were alive when 
taken out. Embryonic day (E) E15.5 as well as E18 entire digestive blocks were dissected 
under a microscope (Leica, Rueil-Malmaison, France) in PBS containing 0.37% formalin to 
preserve tissue integrity. DNA extracted from the legs was used to genotype the fetuses by 
PCR, using primers GR12 (5’-CATGCTGCTAGGCAAATGATCTTAAC) and GR15 (5’-
GAATGAGAATGGCCATGTACTAC) that amplify a 450-bp band for GRnull allele, and 
GR12 and GR30 (5’-CTTCCACTGCTCTTTTAAAGAAGAC) that amplify a 280-bp 
fragment for the wild-type allele.  
 
Fixation and tissue processing The entire digestive blocks from E18 fetuses as well as 
pancreata from E15.5 fetuses and adult GR+/null and GR+/+ mice were fixed in 3.7% formalin 
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solution, dehydrated and embedded in paraffin, as previously described [29]. Tissues were 
entirely cut into 6-µm-thick sections, transversally for the digestive blocks and sagitally for 
the pancreata. The sections were collected on poly-L-lysine-coated slides, left at 37°C 
overnight and stored at 4°C until processed for immunohistochemistry. 
 
Graft experiments Embryonic pancreata from three GRnull/null and three GR+/+ E15.5 fetuses 
were dissected under a microscope and fetuses were genotyped for the GRnull allele. The 
pancreas was introduced into a polycarbonate cylinder (3.35 mm diameter×1.2 mm height) to 
provide a spatial limit to the graft [32] prior to being transplanted under the left kidney 
capsule of 7-week-old SCID mice previously anaesthetised with Hypnomidate (Janssen-Cilag, 
Issy-les-Moulineaux, France). One pancreas was implanted per kidney in each SCID mouse. 
Seven days after the implantation, the SCID mice were injected with 5-bromo-2’-
deoxyuridine (BrdU) (50 mg/kg; Sigma, Saint Quentin Fallavier, France) 1 h before killing, 
and the grafts were removed. Grafted tissues with part of the adjacent kidney were fixed, 
sectioned throughout their length and processed for immunohistochemistry as described 
below. 
 
Immunohistochemistry    
Tissue sections were submitted to a 12-min microwave treatment after boiling in citrate buffer 
(Antigen Retrieval Citra Solution; Biogenex, Alphelys, Plaisir, France), permeabilised for 20 
min with 0.1% Triton X-100 in TBS and incubated 30 min with a blocking buffer (0.1% 
Tween 20 in 3% BSA in TBS) prior to an overnight incubation with primary antibodies at 
4°C. Secondary antibodies (1:200) were incubated for 1–4 h at room temperature. Double 
immunohistochemistry was performed using fluorescent-dye-coupled secondary antibodies 
visualised under a Leica DMR microscope, or alternatively using enzyme-linked secondary 
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antibodies revealed by diaminobenzidine or Fast Red substrates (Dako, Trappes, France). The 
antibodies used are described below. 
 Primary antibodies were: rabbit anti-Pdx-1 [33]; mouse anti-insulin (Sigma); mouse 
anti-BrdU (Amersham Pharmacia Biotech Europe GmbH, Saclay, France); rabbit anti-
glucagon (Diasorin, Stillwater, MN, USA); rabbit anti-amylase (Sigma); rabbit anti-
neurogenin 3 (kind gift of M. S. German); guinea-pig anti-insulin (Dako); and rabbit anti-GR 
(M20; Santa Cruz Biotechnology, Tebu-Bio, Le Perray en Yvelines, France). The rabbit 
antiserum against exocrine transcription factor Ptf1a was raised for us by Neosystem 
(Strasbourg, France) against a synthetic amino acid peptide (C-KSFDNIENEPPFEFVS) 
corresponding to the carboxyl-terminal 16 amino acids of mouse and rat Ptf1a. For 
immunisation the peptide was coupled to keyhole limpet haemocyanin through a cysteine 
included as the amino terminus of the peptide. 
 Secondary antibodies were: FITC-labelled anti-guinea-pig; FITC-labelled anti-rabbit; 
Texas Red-labelled anti-mouse; Texas Red-labelled anti-rabbit; peroxidase-conjugated anti-
guinea-pig; biotin-conjugated anti-rabbit (Immunotech-Beckman Coulter, Marseille, France); 
and peroxidase-conjugated anti-rabbit (Promega, Charbonnieres, France). Biotin-coupled 
antibodies were revealed using alkaline phosphatase-conjugated streptavidin (BioGenex) or 
peroxidase-conjugated streptavidin (Amersham Pharmacia Biotech). Peroxidase was detected 
with diaminobenzidine and alkaline phosphatase with Fast Red substrate. 
 
Detection of apoptosis Cell death was examined using the terminal transferase-mediated X-
dUTP nick end labelling (TUNEL) method with an Apoptag Apoptosis Detection Kit 
(Intergen, MP Biomedicals, Illkirch, France). Apoptotic nuclei were stained in red with Fast 
Red substrate. 
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Beta cell fraction measurements The beta cell fraction (per cent beta cells in the pancreas) was 
measured as the ratio of the insulin-positive cell area to the total tissue area on the entire 
section. Pancreatic tissue area and insulin-positive cell area were determined by computer-
assisted measurements using a Leica DMRB microscope equipped with a colour video camera 
coupled to a Q500IW computer (screen magnification ×24), as previously described [27]. 
Morphometrical analysis was performed on ten transversal and 240-µm-spaced sections from 
wild-type and GR+/null E18 digestive blocks (n=5). Pancreata from wild-type and GRnull/null 
fetuses at E15.5 (n=3) and from wild-type and GR+/null adult mice at 3 months of age (n=4) 
were sectioned throughout their length and the morphometrical analysis was performed on 
seven or eight 150-µm-spaced sections per pancreas. The pancreatic volume of GRnull/null and 
GR+/+ E15.5 fetuses was estimated on the sectioned digestive blocks by multiplying the total 
pancreatic area morphometrically measured on every tenth section, the number of sections 
and their thickness. The pancreatic volume of three GRnull/null mutants was expressed as a 
percentage of the mean control volume (n=3). 
 
Quantification of beta cell proliferation and islet number in the grafts Dual 
immunohistochemistry for BrdU and insulin was performed as previously described [29] and 
proliferation was expressed as the percentage of insulin-positive cells showing a BrdU-
positive nucleus. The number of islets composed of at least two insulin-positive cells 
associated with one glucagon-positive cell was counted on every fifth section of the grafts 
throughout their length. 
 
Statistical analysis All results are expressed as means±SEM. The statistical significance of 
variations for beta cell fraction was tested by a Mann–Whitney non-parametric test. p values 
<0.05 were considered significant. 
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Results 
 
As GRnull/null mice die at birth [24] we studied the pancreas of these mice at embryonic stage 
E18. The whole digestive tract from GRnull/null mutants was smaller and displayed a pale 
colour, especially the spleen, compared with the GR+/+ littermates (Fig. 1a,b). Although both 
the head and the tail of the pancreas were present, the volume of the whole pancreas of 
GRnull/null mice was 17.3±3.1% that of wild-type littermates, a bigger decrease than that in the 
other digestive organs (Fig. 1a,b). Histologically, despite the presence of all pancreatic cell 
types, both endocrine and exocrine, no organisation into islets or acini was found (Fig. 1c–f). 
Beside this lack of structural organisation, insulin immunoreactivity was present, although at 
weaker levels in E18 GRnull/null fetuses, whereas Pdx-1 immunoreactivity was absent, in 
striking contrast with the exclusive expression of this marker in insulin-positive cells in 
control fetuses (Fig. 1g,h). Finally, TUNEL staining showed that the vast majority of 
pancreatic cells including beta cells were apoptotic in the mutant fetuses compared with wild-
type littermates, suggesting that this tissue was dying (Fig. 1i,j), although all mutant fetuses 
were alive when taken out from the dams. The beta cell fraction was therefore not measurable 
at this stage in the GRnull/null mutants.  
 To gain further insight into the role of the GR, and in particular to investigate the time 
when it could affect pancreatic development, we studied E15.5 GRnull/null fetuses. The pancreas 
appeared normal with well-formed acini and abundant clusters of endocrine cells (Fig. 2a,b). 
The beta cell fraction representing the ratio of insulin-positive area to the total tissue area was 
similar in both groups (Fig. 2k). Further characterisation of the pancreatic tissue at E15.5 
showed abundant Pdx-1-immunoreactive cells (Fig. 2c,d) in controls and null mutants, few of 
which  were also positive for insulin, a consistent observation for this stage of development. 
Ptf1a-positive cells, as well as endocrine precursor cells immunoreactive for neurogenin 3 
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were detected similarly in both wild-type and GRnull/null E15.5 fetuses (Fig. 2e–h). No 
apoptosis could be observed in either control (GR+/+) or GRnull/null fetal pancreata (data not 
shown). At this stage the GR was present in acinar cells, as well as in beta and alpha cells in 
GR+/+ fetuses (Fig. 2i). Somatostatin and pancreatic polypeptide cells could not be visualised 
at this early stage. Taken together these data indicate that pancreatic differentiation in 
GRnull/null fetuses had proceeded normally until E15.5 despite the absence of the GR (Fig. 2j) 
and that the glucocorticoid-sensitive period probably lies at a later fetal stage. 
 To discriminate which elements of the E18 GRnull/null mutant phenotype were due to the 
absence of GR in the pancreas or the environment, pancreata from GRnull/null or GR+/+ 
littermates at E15.5 were grafted for 7 days under the renal capsule of SCID mice. A large 
number of ducts immunoreactive for pan-cytokeratin (Fig. 3a,b) developed in grafted 
pancreata from both groups. Neurogenin 3-positive pro-endocrine cells were not detected any 
more, either in control or in GRnull/null grafts (results not shown). Islet-like structures composed 
of insulin cells surrounded by glucagon cells were present in grafted GRnull/null and control 
pancreata (Fig. 3c,d). The number of these islet-like structures showed a tendency to be 
increased in GRnull/null grafts (36±6 islets vs 16±8 in GR+/+, p=0.12), but the difference did not 
reach statistical significance. Moreover, most of the insulin-positive cells were also positive 
for Pdx-1 (Fig. 3e,f), proliferated similarly in both types of grafts (17±8% in GRnull/null vs 
20±6% in GR+/+, Fig. 3g,h) and did not show any apoptosis (data not shown). These results 
showed that the massive cell death observed at E18 in the GRnull/null mice was rescued and that 
the pancreatic islet cells from this fetal tissue had matured and proliferated normally when 
E15.5 GRnull/null pancreata were grafted in a GR-expressing adult environment.  
 To study a possible dosage effect of the GR on pancreatic and islet development we 
studied heterozygous GR+/null E18 fetuses and adult mice in which the number of GR is 
reduced. The overall pancreatic architecture of E18 GR+/null fetuses was similar to that of GR+/+ 
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littermates and no apoptosis was observed (results not shown). The beta cell fraction in the 
pancreas was increased twofold in the heterozygous mutants as compared with that of E18 
GR+/+ littermates, indicating a negative role for the GR in late beta cell development and 
expansion (Fig. 4). Interestingly the increased beta cell fraction persisted in 3-month-old adult 
heterozygous mice (Fig. 4); however, no difference in glucose tolerance was found in 
heterozygous animals compared with their wild-type littermates (results not shown). 
 
Discussion 
Several studies have suggested that fetal overexposure to glucocorticoids can alter pancreatic 
development and thereby programme consequences for glucose homeostasis in the adult [28, 
29, 34]. From our previous work investigating the direct effects of glucocorticoids on 
pancreatic development by inactivating the GR either in all pancreatic progenitors (GRPdx-Cre 
mice) or specifically in insulin cells (GRRIP-Cre mice) we could conclude that the GR is not 
necessary for beta cell development but rather prevents it through a direct effect on pancreatic 
progenitors [29]. By studying mice deleted for the GR in the whole organism (GRnull/null mice) 
we show here that the GR is not required for the early induction of pancreatic development 
and differentiation but is nevertheless necessary in the pancreatic environment, and thereby 
through indirect effects, for pancreatic morphogenesis during late fetal development. 
Moreover, heterozygous mutants with reduced GR showed an increased beta cell fraction, 
further documenting the negative role of glucocorticoids on beta cell development and 
strengthening the importance of a precise GR dosage to control beta cell mass expansion. 
We first show that pancreatic development proceeds normally until E15.5 in the GRnull/null 
mutant. The tissue structure was similar in mutant and wild-type mice, showing exocrine cells 
organised into acini and insulin and glucagon cells grouped into small endocrine clusters. 
Moreover, all cell populations existing in wild-type fetuses were also present in mutants: 
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precursor cells immunoreactive for Pdx-1 but not insulin, endocrine precursor cells positive 
for neurogenin 3, together with already differentiated exocrine cells positive for Ptf1a and 
amylase, or endocrine cells producing insulin. Finally, morphometrical measurements showed 
a beta cell fraction identical between wild-type and GRnull/null fetuses. Taken together, these 
results show that the GR is not necessary either for the first steps of pancreatic development 
taking place before E15.5, including pancreatic patterning of the endoderm, budding and 
ramification, or for the expansion of the beta cell mass until this stage. On the contrary, 
profound defects were seen in E18 GRnull/null fetuses, among which was a general reduction in 
the size of all organs composing the digestive tract associated with a massive apoptotic rate. 
However, even though it seems to be a general death process the pancreas was much more 
altered than the other organs as its volume represented only 17% of that of an age-matched 
wild-type pancreas. The exponential pancreatic growth during the last days of pregnancy is a 
likely explanation for these defects being more acute in the pancreas than in other organs. The 
explanation for the large number of apoptotic cells in the GRnull/null pancreas at E18 remains 
unclear; it could be either the cause or the consequence of the lack of structure observed. 
However, glucocorticoid levels have already been reported to play a role in the apoptotic 
process of various endodermally derived cell types. More precisely, it has been shown that 
dexamethasone treatment leads to an increased expression of the anti-apoptotic factors Bcl-2, 
Bcl-xL or cFLIP (an inhibitor of caspase-8) in human and rat hepatocytes [35], or c-IAP2 
(cellular inhibitor of apoptosis 2) in human lung epithelial cells [36]. Moreover, Wistar 
Bonn/Kobori rats, which spontaneously develop chronic pancreatitis, have a decreased 
pancreatic weight, low endogenous corticosterone levels and increased acinar cell apoptosis 
[37]. In this rat model, acinar cell apoptosis can be attenuated by prednisolone treatment, 
strengthening the role of glucocorticoids in maintaining a low apoptotic rate in the pancreas, 
possibly by decreasing inflammation. 
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 Taken together these studies show a anti-apoptotic role of glucocorticoids consistent 
with the spectacularly increased apoptotic rate observed in the whole digestive tract of GR-
deficient mice. Finally, as pancreatic apoptosis was rescued in E18 GR+/null heterozygous 
mutants, we demonstrate that low levels of GR are sufficient to prevent pancreatic cell death.  
 The graft experiments allowed us to discriminate which elements of the E18 GRnull/null 
pancreatic phenotype were due to the absence of glucocorticoid signalling in the pancreas or 
the environment, i.e. discriminate between direct and indirect effects. The grafted tissue 
demonstrated normal organisation and fully differentiated endocrine cells in islets, with Pdx-1 
immunoreactivity restricted to insulin-positive cells and the disappearance of neurogenin 3-
positive cells. The increased apoptosis observed in E18 GRnull/null fetuses was rescued upon 
grafting E15.5 mutant pancreata into SCID mice, a GR-expressing environment, thus 
demonstrating that GRnull/null pancreatic cell death can be attributed to indirect effects of 
glucocorticoids on this tissue. Such a situation where GR is absent only in the pancreas 
resembles that of GRPdx-Cre mice showing no defects in pancreatic tissue structure [29], 
strengthening the importance of a GR-expressing environment to preserve pancreatic 
structure. These results also allow us to define a critical developmental period, after E15.5 and 
probably before E18, when pancreatic viability is particularly dependent on GR function in 
the environment. Interestingly, this time period coincides with high GR expression in the 
pancreas as well as several other organs such as the liver, intestine, kidney and placenta [4], 
suggesting that these organs, sensitive to glucocorticoids, could relay the indirect effects of 
glucocorticoids on the pancreas. The mechanisms underlying this massive cell death are far 
from being deciphered and would require thorough investigations of multiple fields. 
Nevertheless, several mechanisms can be proposed. First, these mutants show defective 
erythropoiesis [6, 24], a defect which could contribute to the massive cell death. Another 
plausible cause, in line with the pale colour of the spleen and of all organs composing the 
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digestive tract, could be impaired vascularisation. However, pancreatic platelet/endothelial 
cell adhesion molecule-1  staining did not show any obvious abnormalities (data not 
shown). Secondly, the absence of GR could involve the lack of glucocorticoid-dependent 
production by other organs of factors favouring  pancreatic survival. Alternatively, GR 
deficiency may also induce the production of pro-apoptotic factors by the environment.  
 Beside these indirect effects on pancreatic survival, glucocorticoids also show direct 
effects on beta cell expansion. Our former experiments inactivating the GR in the pancreatic 
progenitors (GRPdx-Cre mice) showed that the GR was not necessary for pancreatic 
morphogenesis and its absence rather increased beta cell mass [29]. Interestingly, our 
observations in heterozygous GR+/null mutants, with reduced GR in the whole organism, 
similarly show a markedly increased beta cell fraction at E18 that persisted in adults. In line 
with this finding we also observed slightly increased islet numbers in the grafts originating 
from GRnull/null fetuses compared with those from control fetuses, but the small numbers of 
grafts did not allow us to show any significant difference. This pancreatic phenotype, also 
similar to that of GRPdx-Cre mice [29], confirms our earlier finding regarding a direct action of 
the GR signalling pathway on beta cell expansion, but more importantly strengthens the idea 
of an accurate GR dosage on the control of this expansion. This suggests that any changes 
leading to modifications of the glucocorticoid signalling pathway (GR protein level and 
affinity, glucocorticoid circulating levels, cofactor availability) could affect beta cell mass 
when fluctuating within a physiological range. The observation that the heterozygous 
mutation of the gene encoding GR led to a strong pancreatic phenotype suggests that natural 
variations in GR expression could have similar consequences in humans. It would therefore 
be of the greatest interest to look at polymorphisms of the gene encoding GR in both normal 
and diabetic populations, as well as in non-diabetic obese adults, in whom the beta cell mass 
has been suggested as being protective against diabetes [38].  
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 To summarise, we have shown that the glucocorticoid signalling pathway is not 
required for early steps of pancreatic development before E15.5. On the contrary, we define a 
critical period in late fetal life when glucocorticoid signalling is necessary both to maintain 
pancreatic survival through indirect effects and to control beta cell mass through direct 
effects. Moreover, these two different effects are sensitive to different levels of activation of 
the GR. In the context of fetal programming of the metabolic syndrome by glucocorticoids, 
preventing glucocorticoids overexposure is thereby not sufficient; it is necessary to focus on 
how to maintain glucocorticoid signalling in a defined range of activation. 
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Fig. 1 Dramatic growth failure and organisation of the E18 GRnull/null pancreas. At E18, 
GRnull/null mutants (b, d, f, h, j) show a profound growth failure of the whole digestive tract 
compared with their wild-type (wt) littermates (a, c, e, g, i). The pancreatic volume (dashed 
line) was even more dramatically reduced than the other digestive organs in the mutant (b). 
Histological staining (c, d) and double immunohistochemistry for insulin (pink) and amylase 
(brown) (e, f) showed a totally disorganised pancreatic structure with no acini or islets in the 
null mutant, despite the presence of insulin- or amylase-expressing cells. Insulin-expressing 
cells from GRnull/null mutants (red, h) stained faintly for the hormone and did not express Pdx-1 
(green, h), whereas most insulin-positive cells from wild-type fetuses expressed Pdx-1 (g). In 
the GRnull/null mutant (j) numerous insulin-expressing cells (brown; arrowheads in inset) as 
well as acinar cells displayed positive TUNEL staining, but not in the control littermates (i). 
Scale bars=50 µm (c–f) and 25 µm (g–j) 
  
 
Fig. 2 The pancreas is organised normally in GRnull/null mutants at E15.5. At E15.5, GRnull/null 
pancreata (b, d, f, h, j) show well-formed acini (brown) with amylase immunostaining (a, b) 
and endocrine cell clusters (red) using a mixture of anti-insulin (Ins) and anti-glucagon (Glu) 
antibodies (a, b), similar to those of their wild-type (wt) littermates. GRnull/null mice show the 
same differentiation status as their wild-type littermates at E15.5, as shown by the numerous 
precursor cells expressing Pdx-1 (green fluorescent nuclei, c, d), or the pro-endocrine marker 
neurogenin 3 (pink nuclei, e, f), and cells expressing the exocrine marker Ptf1a (pink nuclei, g, 
h). At this stage, only few Pdx-1-expressing cells also expressed insulin (red fluorescent 
staining, c, d). In the GRnull/null fetuses GR was not expressed in exocrine cells, or in alpha 
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cells (j) or beta cells (inset in j), whereas immunopositive nuclei (brown) can be detected in 
acinar cells (arrows) as well as in alpha cells (arrowheads in i) and insulin cells (arrowheads, 
inset in i) in wild-type littermates. Beta-cell fraction analysed as the ratio of insulin-positive 
area to the total tissue area (k) was indistinguishable in GRnull/null and wild-type (GR+/+ 
littermates) fetal pancreata at that stage (n=3 animals per group, means±SEM). Scale bars=50 
µm, except c, d, 25 µm  
 
Fig. 3 Rescue of endocrine differentiation upon grafting the GRnull/null pancreas. Three 
pancreata from GRnull/null (b, d, f, h) or GR+/+ littermates (a, c, e, g) fetuses at E15.5 were 
grafted for 7 days under the kidney capsule of SCID mice. One hour before killing, the 
animals were injected with BrdU, as described in Material and methods. Both groups of 
grafted tissue showed indistinguishable immunohistochemical patterns: ducts expressing pan-
cytokeratin (panCK) (red, a, b) were intermingled with endocrine cell clusters (green, a, b). 
Islets were composed of glucagon-expressing cells (red, c, d) surrounding a core of insulin 
(Ins)-positive cells (green, c, d). All the insulin-positive cells (red, e, f) had matured and 
expressed Pdx-1 (green nuclei, e, f). Beta-cell proliferation rates analysed by double 
immunohistochemistry for BrdU (red nuclei) and insulin (green) were identical in both 
groups of grafted tissue (g, h). k, kidney; wt, wild-type. Scale bars=50 µm (a–d) and 25 µm 
(e–h) 
 
Fig. 4 Reducing GR numbers (GR+/null) increases the beta-cell fraction in E18 and adult 
pancreata. Beta-cell fraction, analysed as the ratio of insulin-positive area to the total tissue 
area, was increased twofold in GR+/null E18 fetuses (a) and 1.3-fold in GR+/null adults (b) 
compared with that of wild-type age-matched animals. *p<0.05, Mann–Whitney non-
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parametrical test; n=5 and n=4 (means±SEM) in both groups in E18 fetuses and adult 
animals, respectively 
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